miR-181a-5p promotes the progression of gastric cancer via RASSF6-mediated MAPK signalling activation

Publication date: 28 March 2017
Source:Cancer Letters, Volume 389
Author(s): Yushuai Mi, Dongyuan Zhang, Weiliang Jiang, Junyong Weng, Chongzhi Zhou, Kejian Huang, Huamei Tang, Yang Yu, Xisheng Liu, Weiyingqi Cui, Meng Zhang, Xiaofeng Sun, Zongguang Zhou, Zhihai Peng, Senlin Zhao, Yugang Wen
We previously discovered that Ras association domain family member 6 (RASSF6) was downregulated and predicted poor prognosis in GC patients. However, the mechanisms of the down regulation of RASSF6 in GC remained unclear. Increasing evidence indicates that dysregulation of microRNAs promotes the progression of cancer through the repression of tumour suppressors. Here, we identified miR-181a-5p as a novel regulator of RASSF6 in GC. Functionally, ectopic expression or silencing of miR-181a-5p, respectively, promoted or inhibited GC cell proliferation, colony formation and cell cycle transition, as well as enhanced or prevented the invasion, metastasis of GC cells and epithelial to mesenchymal transition of GC cells in vitro and in vivo. Molecularly, miR-181a-5p functioned as an onco-miRNA by activating the RASSF6-regulated MAKP pathway. Overexpression or silencing of RASSF6 could partially reverse the effects of the overexpression or repression of miR-181a-5p on GC progress caused by activation of the MAKP pathway in vitro and in vivo. Clinically, high miR-181a-5p expression predicted poor survival in GC patients, especially combined with low RASSF6 expression. Collectively, we identified miR-181a-5p as an onco-miRNA, which acts by directly repressing RASSF6 in GC.



from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2iFxR24
via IFTTT